A NEW study published by The BMJ has found that diabetes drug metformin is not associated with birth defects.
As a result, it is a suitable medication for potential fathers with type 2 diabetes.
The finding follows a recent Danish study linking men on metformin and an increased risk of congenital malformations in male infants.
Researchers further evaluated this connection in offspring from Norway and Taiwan.
"After restricting analyses to fathers with type 2 diabetes, and adjusting for other important factors, such as father's age and related conditions, no increased risk of any congenital malformations among infants born to fathers who used metformin during the sperm development period was found in either Norway or Taiwan," said the researchers.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 24
